Michael A. Foley
Michael Foley joined the Broad Institute in 2006 and now serves as director of the Therapeutics Platform. He brings extensive knowledge of chemistry and chemical technology, including techniques based on diversity-oriented synthesis (DOS) and medicinal chemistry. Under his leadership, the platform oversees all aspects of chemical libraries and high-throughput chemical screening at the Broad. The platform works to systematically create DOS libraries and develop new approaches to target identification for cell-based screens.
Foley was a co-founder of Infinity Pharmaceuticals and served as Vice President of Chemistry from 2001 to 2006. He was also a co-founder of CombinatoRx Inc. and Forma Therapeutics Inc., and previously worked at Bristol-Myers Squibb and GlaxoSmithKline. He obtained his Ph.D. at Harvard, and helped establish the Harvard Institute of Chemistry and Cell Biology.
Foley received a B.S. in chemistry from St. Norbert College, an M.S. in chemistry from Utah State University, and a Ph.D. in chemistry from Harvard University.